Genetic Signatures

Genetic Signatures Limited – Annual Report 2021 Directors’ Report DIRECTORS’ REPORT FOR THE FINANCIAL YEAR ENDED 30 JUNE 2021 6 Name: Anthony J Radford AO FTSE Qualifications: BSc (Hons) PhD DipCorpMan Experience: Dr. Anthony Radford has a PhD from La Trobe University, and was a member of the CSIRO team that invented the QuantiFERON method for Cellular Immune based diagnostics. He later joined AMRAD in pharmaceutical research and was Head of Development in 2000 when he left to co-found the diagnostic company Cellestis Limited, which listed on the ASX in 2001. Establishing offices and operations in the USA, Europe and Japan, Cellestis developed QuantiFERON –TB Gold, the worldwide benchmark for diagnosis of tuberculosis infection. Dr. Radford was CEO of Cellestis from founding until its acquisition by QIAGEN NV in 2011. He is a Fellow of the Australian Academy of Technology and Engineering, and a recipient of their Clunies Ross Prize. Special responsibilities: Non-Executive; Member of Audit & Risk Committee and Nomination & Remuneration Committee Directorships of other listed companies: Nil Interests in shares and options: 240,000 ordinary shares Name: Neil Gunn (appointed 6 April 2021) Qualifications: BSc, Msc, PhD Experience: Dr Gunn holds a PhD and Master of Science from Portsmouth Polytechnic, UK. He has over 30 years’ experience in medical devices and diagnostics. Most recently he was the President of Roche Sequencing Solutions where he oversaw all aspects of the business and managed a team of approximately 900 people. His team developed and launched more than 20 products per year. Prior to this he was Vice President of Roche’s Molecular Diagnostics business and was responsible for over 120 diagnostic product launches principally into the IVD clinical market. Dr Gunn is based in San Francisco, USA. Special responsibilities: None Directorships of other listed companies: Nil Interests in shares and options: Nil